Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF
暂无分享,去创建一个
J. Ritz | R. Soiffer | S. Herrmann | M. Robertson | D. Young | S. Wolf | R. Soiffer | T. Manley | C. Donahue | Thomas J. Manley | Deborah Young | Stanley Wolf | Christopher Donahue | S. Wolf | D. Young
[1] J. Ritz,et al. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells , 1992, European journal of immunology.
[2] F. Podlaski,et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). , 1991, Journal of immunology.
[3] D. Cosman,et al. Homology of the p40 subunit of natural killer cell stimulatory factor (NKSF) with the extracellular domain of the interleukin-6 receptor , 1991, Cell.
[4] P. Familletti,et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[5] R. Hewick,et al. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. , 1991, Journal of immunology.
[6] G. Trinchieri,et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.
[7] J. Ritz,et al. Biology and clinical relevance of human natural killer cells. , 1990, Blood.
[8] C. Gahmberg,et al. Participation of CD11a‐c/CD18, CD2 and ROD‐binding receptors in endogenous and interleukin‐2‐stimulated NK activity of CDS‐negative large granular lymphocytes , 1990, International journal of cancer.
[9] M. Caligiuri,et al. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. , 1990, Journal of immunology.
[10] F. Podlaski,et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[11] M. Caligiuri,et al. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors , 1990, The Journal of experimental medicine.
[12] T. Uchiyama,et al. Selective expression of the p70 subunit of the interleukin-2 receptor on lymphocytes from patients with infectious mononucleosis. , 1990, Blood.
[13] R. Kaufman. Strategies for obtaining high level expression in mammalian cells. , 1990 .
[14] G. Trinchieri,et al. Biology of Natural Killer Cells , 1989, Advances in Immunology.
[15] L. Lanier,et al. Comparative studies of human FcRIII-positive and negative natural killer cells. , 1989, Journal of immunology.
[16] W. Linehan,et al. Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients , 1989, Annals of surgery.
[17] G. Trinchieri,et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes , 1989, Journal of Experimental Medicine.
[18] R. Fisher,et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Fisher,et al. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Jones,et al. Phase II trial of outpatient interleukin-2 in malignant lymphoma, chronic lymphocytic leukemia, and selected solid tumors. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Gahmberg,et al. CD11a-c/CD18 and GP84 (LB-2) adhesion molecules on human large granular lymphocytes and their participation in natural killing. , 1988, Journal of immunology.
[22] R. Bechhofer,et al. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. , 1988, Cancer research.
[23] W. Greene,et al. Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.
[24] L. Lanier,et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Leonard,et al. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.
[26] W. Chan,et al. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[27] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[28] E. Reinherz,et al. Enhancement of natural killer function through activation of the T11 E rosette receptor. , 1987, The Journal of clinical investigation.
[29] K C Zoon,et al. Interferons and their actions. , 1987, Annual review of biochemistry.
[30] G. Trinchieri,et al. Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. , 1986, Journal of immunology.
[31] L. Lanier,et al. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.
[32] S. Rosenberg,et al. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. , 1985, Cancer research.
[33] E. Reinherz,et al. Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. , 1985, Science.
[34] L. Lanier,et al. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. , 1985, Journal of immunology.
[35] C. Balch,et al. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. , 1985, Journal of immunology.
[36] G. Trinchieri,et al. Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.
[37] S. Rosenberg,et al. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. , 1984, Science.